Premium
Cefotaxime as the potential cause of transient acquired von Willebrand syndrome
Author(s) -
Haj M. A.,
Murch N.,
Bowen D. J.,
Sati H. I.,
Beddal A.,
Benton A.,
Collins P.
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.0902-4441.2006.t01-1-ejh2386.x
Subject(s) - cefotaxime , medicine , transient (computer programming) , von willebrand disease , cardiology , pediatrics , von willebrand factor , computer science , microbiology and biotechnology , biology , antibiotics , platelet , operating system
Abstract: Acquired von Willebrand syndrome (AvWS) is a relatively rare bleeding disorder. It has been reported in association with myeloproliferative disorders, autoimmune diseases, plasma cell dyscrasias and certain drugs. Cefotaxime is a third generation cephalosporin widely used for surgical prophylaxis and as empirical treatment of bacterial meningitis. We report a case of a transient AvWS in association with cefotaxime therapy.